Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics (Nasdaq: KPTI) granted an inducement equity award to a newly hired employee under its 2022 Inducement Stock Incentive Plan.

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted an inducement equity award to a newly hired employee under its 2022 Inducement Stock Incentive Plan. The award consists of 1,200 restricted stock units (RSUs), granted on May 31, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to the employee’s continued service with Karyopharm.

Argus Jun 2 session

-6.01% close to close Open Argus

Details

News Market Reaction – KPTI

On Jun 2, the first trading day after this news, KPTI closed 6.01% below the previous close.

Data tracked by StockTitan Argus for the Jun 2 session.

Key Figures

RSU grant size: 1,200 RSUs Vesting period: 3 years Annual vesting rate: 33 1/3% +5 more

RSU grant size

1,200 RSUs

Inducement grant to one new employee as of May 31, 2026

Vesting period

3 years

RSUs vest over three consecutive anniversaries of the Grant Date

Annual vesting rate

33 1/3%

Portion of RSU award vesting on each anniversary over three years

Current price

$9.10

Price before news; about 17.2% below 52-week high

52-week range

$3.6503–$10.99

Low to high range prior to this announcement

Registered resale shares

8,843,036 shares

Shares covered by effective registration statement filed May 4, 2026

Private placement proceeds

$30 million

Gross proceeds from March 2026 private placement tied to registration

Ownership cap

9.99%

Beneficial ownership limit on warrant exercises in registration

Historical Context

5 past events · Latest: May 28

5 events

1. May 28

   Conference participation

   24h Move

   +1.4%

   Management slated for Jefferies healthcare conference fireside chat with webcast access.

2. May 14

   Earnings & trials

   24h Move

   +0.6%

   Q1 2026 results, revenue guidance reaffirmation, and key Phase 3 trial milestones.

3. May 12

   Investor conferences

   24h Move

   +1.2%

   Participation in multiple May 2026 investor conferences via fireside chats.

4. May 07

   Earnings date set

   24h Move

   -1.9%

   Announcement of timing and webcast details for Q1 2026 earnings release.

5. Apr 21

   ASCO late-breaker

   24h Move

   +2.6%

   Phase 3 SENTRY myelofibrosis data selected for late-breaking oral ASCO 2026 slot.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, rsus, nasdaq listing rule 5635(c)(4)

3 terms

restricted stock units financial

"the Company granted 1,200 restricted stock units (RSUs) to one newly-hired employee"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

rsus financial

"1,200 restricted stock units (RSUs) to one newly-hired employee"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

nasdaq listing rule 5635(c)(4) regulatory

"as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 1,200 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of May 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO^® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO^® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematologic and solid tumor cancers, including in myelofibrosis and TP53 wild-type endometrial cancer. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms and TP53 wild-type driven solid tumors using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-302786006.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grant did Karyopharm Therapeutics (KPTI) announce on June 1, 2026?

Karyopharm Therapeutics announced an inducement grant of 1,200 restricted stock units (RSUs) to one newly hired employee. According to Karyopharm, the grant was made under its 2022 Inducement Stock Incentive Plan as an employment inducement.

When was the Karyopharm Therapeutics (KPTI) inducement RSU grant effective?

The inducement RSU grant became effective on May 31, 2026, designated as the grant date. According to Karyopharm, this date governs the vesting schedule, with RSUs vesting on each of the three consecutive anniversaries of the grant date.

How do the 1,200 RSUs granted by Karyopharm (KPTI) vest over time?

The 1,200 RSUs vest in three equal annual installments of 33 1/3% each year. According to Karyopharm, vesting occurs on each of the three anniversaries of the May 31, 2026 grant date, subject to continued service.

What conditions apply to the vesting of Karyopharm Therapeutics (KPTI) inducement RSUs?

Vesting of the RSUs requires the employee’s continued service with Karyopharm or as another service provider. According to Karyopharm, RSUs vest only if the individual remains in service through each applicable vesting date.

Under which plan were the 1,200 Karyopharm (KPTI) inducement RSUs granted?

The RSUs were granted under Karyopharm’s 2022 Inducement Stock Incentive Plan, as amended. According to Karyopharm, this plan supports equity awards used as a material inducement for new employees joining the company.

How is Nasdaq Listing Rule 5635(c)(4) related to Karyopharm’s (KPTI) inducement RSU grant?

Karyopharm stated the RSU grant was made in accordance with Nasdaq Listing Rule 5635(c)(4). According to Karyopharm, the award serves as a material inducement for the new employee to enter into employment with the company.